Islet Recovery and Reversal of Murine Type 1 Diabetes in the Absence of Any Infused Spleen Cell Contribution

A cure for type 1 diabetes will probably require the provision or elicitation of new pancreatic islet {szligbeta} cells as well as the reestablishment of immunological tolerance. A 2003 study reported achievement of both advances in the NOD mouse model by coupling injection of Freund's complete...

Full description

Saved in:
Bibliographic Details
Published in:Science (American Association for the Advancement of Science) 2006-03, Vol.311 (5768), p.1775-1778
Main Authors: Nishio, Junko, Gaglia, Jason L, Turvey, Stuart E, Campbell, Christopher, Benoist, Christophe, Mathis, Diane
Format: Article
Language:English
Subjects:
Animals
Antibodies - immunology
Autoimmune diseases
Autoimmunity
Biological and medical sciences
Blood Glucose - analysis
Cell Differentiation
Cell Transplantation
Combined Modality Therapy
Diabetes
Diabetes complications
Diabetes Mellitus, Type 1 - immunology
Diabetes Mellitus, Type 1 - pathology
Diabetes Mellitus, Type 1 - therapy
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Female
Freund's Adjuvant - therapeutic use
Insulin
Insulin-Secreting Cells - cytology
Islets of Langerhans - cytology
Islets of Langerhans - pathology
Islets of Langerhans Transplantation
Male
Management. Various non-drug treatments. Langerhans islet grafts
Medical sciences
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Inbred NOD
Nephrectomy
Polymorphism, Single Nucleotide
Regeneration
Rodents
Spleen
Spleen - cytology
Spleen - immunology
Spleen cells
Splenocytes
Stem cells
Transplantation
Type 1 diabetes mellitus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A cure for type 1 diabetes will probably require the provision or elicitation of new pancreatic islet {szligbeta} cells as well as the reestablishment of immunological tolerance. A 2003 study reported achievement of both advances in the NOD mouse model by coupling injection of Freund's complete adjuvant with infusion of allogeneic spleen cells. It was concluded that the adjuvant eliminated anti-islet autoimmunity and the donor splenocytes differentiated into insulin-producing (presumably {szligbeta}) cells, culminating in islet regeneration. Here, we provide data indicating that the recovered islets were all of host origin, reflecting that the diabetic NOD mice actually retain substantial {szligbeta} cell mass, which can be rejuvenated/regenerated to reverse disease upon adjuvant-dependent dampening of autoimmunity.
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1124004